These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 1971117

  • 1. Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients.
    Minervini MG, Priore P, Farolfi A, Cesana B, Morselli PL.
    Pharmacopsychiatry; 1990 Mar; 23(2):102-6. PubMed ID: 1971117
    [Abstract] [Full Text] [Related]

  • 2. Alpidem, a novel anxiolytic drug. A double-blind, placebo-controlled study in anxious outpatients.
    Bassi S, Albizzati MG, Ferrarese C, Frattola L, Cesana B, Piolti R, Farolfi A.
    Clin Neuropharmacol; 1989 Feb; 12(1):67-74. PubMed ID: 2565767
    [Abstract] [Full Text] [Related]

  • 3. A comparative study of alpidem, a nonbenzodiazepine, and lorazepam in patients with nonpsychotic anxiety.
    Diamond BI, Nguyen H, O'Neal E, Ochs R, Kaffeman M, Borison RL.
    Psychopharmacol Bull; 1991 Feb; 27(1):67-71. PubMed ID: 1677774
    [Abstract] [Full Text] [Related]

  • 4. A double-blind, placebo-controlled study of alpidem, a novel anxiolytic of imidazopyridine structure, in chronically anxious patients.
    Casacchia M, Farolfi A, Priore P, Magni G, Stratta P, Cesana B, Rossi A.
    Acta Psychiatr Scand; 1989 Aug; 80(2):137-41. PubMed ID: 2572145
    [Abstract] [Full Text] [Related]

  • 5. [Double-blind versus placebo comparison of single dose alpidem (50 mg or 75 mg) in a model of situational anxiety].
    Regnier F, Chastel A, L'Heritier C, Magni G, Henry M.
    Therapie; 1989 Aug; 44(4):279-83. PubMed ID: 2574502
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of alpidem in anxious elderly outpatients: a double-blind, placebo-controlled trial.
    Frattola L, Piolti R, Bassi S, Albizzati MG, Cesana BM, Bottani MS, Priore P, Borghi C, Morselli PL.
    Clin Neuropharmacol; 1992 Dec; 15(6):477-87. PubMed ID: 1362137
    [Abstract] [Full Text] [Related]

  • 8. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group.
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [Abstract] [Full Text] [Related]

  • 9. Alpidem and lorazepam in the treatment of patients with anxiety disorders: comparison of physiological and psychological effects.
    Morton S, Lader M.
    Pharmacopsychiatry; 1992 Jul; 25(4):177-81. PubMed ID: 1356277
    [Abstract] [Full Text] [Related]

  • 10. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
    Cutler NR, Sramek JJ, Keppel Hesselink JM, Krol A, Roeschen J, Rickels K, Schweizer E.
    J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF.
    Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
    [Abstract] [Full Text] [Related]

  • 12. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 13. On the therapeutic action of alpidem in anxiety disorders: an overview of the European data.
    Morselli PL.
    Pharmacopsychiatry; 1990 May; 23 Suppl 3():129-34. PubMed ID: 1974073
    [Abstract] [Full Text] [Related]

  • 14. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.
    Pollack MH, Worthington JJ, Manfro GG, Otto MW, Zucker BG.
    J Clin Psychiatry; 1997 May; 58 Suppl 11():19-23. PubMed ID: 9363044
    [Abstract] [Full Text] [Related]

  • 15. Alpidem in the treatment of panic disorder.
    Schneier FR, Carrasco JL, Hollander E, Campeas R, Fallon B, Saoud JB, Feerick J, Liebowitz MR.
    J Clin Psychopharmacol; 1993 Apr; 13(2):150-3. PubMed ID: 8096527
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice.
    Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O.
    Hum Psychopharmacol; 2006 Apr; 21(3):139-49. PubMed ID: 16625522
    [Abstract] [Full Text] [Related]

  • 17. Studies with alpidem in normal volunteers and anxious patients.
    Morton S, Lader M.
    Pharmacopsychiatry; 1990 May; 23 Suppl 3():120-3. PubMed ID: 1974071
    [Abstract] [Full Text] [Related]

  • 18. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ, Riedel M, Müller N, Fischer W, Kohnen R.
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [Abstract] [Full Text] [Related]

  • 19. The efficacy of Cavain in patients suffering from anxiety.
    Lehmann E, Klieser E, Klimke A, Krach H, Spatz R.
    Pharmacopsychiatry; 1989 Nov; 22(6):258-62. PubMed ID: 2575765
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines.
    Malsch U, Kieser M.
    Psychopharmacology (Berl); 2001 Sep; 157(3):277-83. PubMed ID: 11605083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.